Progesterone vaginal - Ferring Pharmaceuticals

Drug Profile

Progesterone vaginal - Ferring Pharmaceuticals

Alternative Names: Endometrin; FE 999 913; FE 99913; Lutinus; Progesterone vaginal tablet - Ferring

Latest Information Update: 22 Dec 2015

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 29 Aug 2013 Ferring completes a phase III trial in Female infertility in Japan (NCT01710514)
  • 22 Jul 2013 Biomarkers information updated
  • 31 Oct 2012 Phase-III clinical trials in Female infertility in Japan (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top